MedTrace Logo

VEL-101 to Prevent Rejection After Kidney Transplantation

NCT07290777 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-18

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.

Conditions

  • Transplantation, Kidney

Interventions

DRUG

Tacrolimus (TAC)

Tacrolimus Immediate Release in addition to SOC

DRUG

VEL-101

VEL-101 in addition to SOC

Sponsors & Collaborators

  • Veloxis Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-10-31
Completion
2028-10-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07290777 on ClinicalTrials.gov